Table 2.
Imaging and Ki-67 results, n = 40
| |
Aromatase inhibitor ( n = 28) |
Trastuzumab ( n = 12) |
||
|---|---|---|---|---|
| n (%) |
Median (min, max) |
n (%) |
Median (min, max) |
|
| SUVmax of index lesion at baseline |
28 |
4.6 (1.6, 18.9) |
12 |
8.9 (2.6, 17.2) |
| Days between FDG PET scans |
28 |
18 (12, 33) |
12 |
15 (13, 29) |
| SUVmax of index lesion at follow-up |
28 |
3.2 (1.2, 13.6) |
12 |
5.3 (1.6, 17.1) |
| Percent change in SUVmax |
28 |
−28 (−60, 11) |
12 |
−25 (−75, 9) |
| Patients with FDG PET early response (≥20% SUV decline) |
20 (71%) |
|
6 (50%) |
|
| Ki-67 prior to run-in therapy (%) |
22 |
15 (<5, 41) |
5 |
40 (5, 60) |
| Days between successful biopsies |
14 |
51 (16, 608) |
3 |
29 (14, 49) |
| Ki-67 following run-in therapy (%) |
14 |
5 (0.5, 60) |
3 |
25 (20, 60) |
| Patients with Ki-67 ≤5% following run-in therapy |
11 (79%) |
|
0 (0%) |
|
| Change in Ki-67 | 14 | −8 (−26, 30) | 3 | 0 (−15, 15) |